Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Neurocrine Biosciences (NBIX) Misses Q3 EPS by 8c, Revenues Beat
November 4, 2019 4:02 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.56, $0.08 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $222.09 million versus the consensus estimate of $211.63 million.
"We are pleased that a record number of new patients initiated treatment with INGREZZA as... More
